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Cascade screeningAbstract Background: Pakistan is the sixth most populous country in the World. High rates of
consanguinity and inter caste marriages have resulted in a substantial burden of inherited metabolic
disorders (IMDs). Despite this load, there is a dearth of both medical genetic and clinical metabolic
services in Pakistan. There are inadequate numbers of appropriately trained clinicians, ill-equipped
laboratories, lack of scientists and technologists equipped with skills to deal with the challenging
laboratory investigations involved in IMD and a health care infra-structure unable to support a ser-
vice.
Aim: We present the first five year experience of the first established metabolic unit at a tertiary
care hospital in Pakistan and present the case for screening of parents, parents’ siblings and ante-
natal diagnostic testing in subsequent pregnancies in order that families can make informed choices
in preventing recurrence.
Subjects and methods: This retrospective observational study comprising of patients’ chart
review was conducted in the Department of Paediatrics, AKUH Karachi in Pakistan for patients
who presented to the Clinical Genetics unit from January 2008 to December 2012 seeking diagnosis
and treatment for the underlying IMD.
Results: We evaluated 426 children, of which, 333 (78%) had consanguineous parents. Most
patients, 151 (35%). evaluated for IMD were between 1 year and 5 years of age. Developmental
delay, seizures, hypotonia, microcephaly, neuroregression, dystonia, ataxia and encephalopathyKarachi
. Naz),
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chemical testing. Among the investigated group of patients, diagnoses were established for 85
(55%) patients equivalent to only 19.8% of the total.
Conclusion: Neonatal screening for IMDs and their treatment in the current situation is an unaf-
fordable practical option in Pakistan. Screening parents, siblings and subsequent pregnancies, how-
ever, is likely to provide a cost effective and acceptable alternative in reducing the burden and
enabling early, effective detection of affected progeny before the stage when neurometabolic
changes become irreversible in developing countries like Pakistan with very limited resources.
 2016 Ain Shams University. Production and hosting by Elsevier B.V. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Inherited metabolic disorders (IMDs) encompass a group of
disorders due to defective metabolic processes. The Cumula-
tive incidence of IEMs varies between 1 in 1400 in British
Columbia [1] and 1 in 3000 in Germany [2]. The measured
prevalence in a particular country depends on the population
selected for screening and the method employed for screening
for IMDs. With the drop in communicable diseases in devel-
oped countries, a demographic switch from communicable dis-
eases to genetic disorders is being observed in many developed
countries. However, establishment of programs for the system-
atic detection of IMDs in developing countries has been a chal-
lenging process [3]. Pakistan faces major health challenges with
high population growth, fertility, and high infant and under-
five mortality. There is uncontrolled burden of communicable
diseases with an increasing problem of non-communicable dis-
eases, which comprised 44% of top 10 causes of mortality/-
morbidity in 2010 [4]. This has resulted in not only lack of
government commitment to invest in this orphan group of dis-
eases but also instilled a belief among physicians in Pakistan
that IMDs are rare diseases, which are untreatable and the
feeling that creating a service does not represent a good use
of already overstretched resources.
The objective of this descriptive study is to report the five
year experience of the first established metabolic unit at a ter-
tiary care hospital in Pakistan. We describe the spectrum of
IMDs seen, challenges faced in reaching a diagnosis, and diffi-
culties encountered in treatment and follow-up. We also pro-
pose some tangible solutions to the unique challenges faced
in establishing genetic and metabolic services in Pakistan.2. Pakistan and its health care structure
Pakistan is a South Asian country and the sixth most populous
nation in the World, having a population of over 184 million
[5]. The country has four provinces; Punjab, Sindh, Khyber
Pakhtunkhwa and Balochistan. The population comprises of
six major ethnic subsets including Punjabis 44.68%, Pathans
15.42%, Sindhis 14.1%, Sariakis 8.38%, Muhajirs 7.57%,
Balochis 3.57% and others 6.28%. Punjabis and Sariakis are
mostly residing in Punjab province, Sindhis and Muhajirs in
Sindh province, Pathans in Kyber Pakhtunkhwa and Balochis
in Balochistan province [6]. Consanguineous marriages and
endogamy are prevalent in Pakistan irrespective of socio-
economic and educational background of different ethnicities.
Consanguinity is present in 65% of all marriages [7] and is amajor contributor to both early and late morbidity and mor-
tality [8].
The WHO has identified Pakistan as one of 57 countries
with critical shortages of health care providers across the globe
[3]. The physician to 1000 person ratio in Pakistan is 0.8 as
compared to 2.4 in USA [9] and the total per capita health
expenditure for Pakistan is USD 39 as compared to USD
8895 in USA [10]. Health care management in Pakistan is
primarily the responsibility of the provincial government.
However, planning and formulation of national health policies
are under the federal government’s control. The health care
system is dichotomized into a small under-utilized public sec-
tor financed by the state and a large independent for profit pri-
vate sector that accounts for 80% of all outpatient health care
[11], for which patients have to pay out of pocket. Thirty-four
percent of the population is urban having some access to effec-
tive health care services [12].
3. Current status of inherited metabolic disorders in Pakistan
Infant and under five mortality rates of Pakistan are 74 per
1000 and 89 per 1000 live births [7]. Birth asphyxia, still birth,
pneumonia, diarrhea, sepsis, neonatal tetanus and congenital
birth defects are attributed major causes of neonatal and infant
mortality in developing countries [13]. Partly as a result of the
attention afforded to these problems, IMDs have been rela-
tively ignored by both the government as well as the private
sector. There is no national birth defect or metabolic diseases
registry established in Pakistan nor is there a newborn screen-
ing program for any IMD in any of the four provinces. Before
2013, only rudimentary metabolic testing was available and
though this has recently marginally expanded, there is little
clinical expertise available for diagnosing and treating patients
with IMDs. Treatment options in the form of food for special
medical purpose (FSMP) and the availability of orphan drugs
is a constant challenge. These factors have resulted in a diffi-
cult situation for physicians, parents and families many of
whom are faced with a gloomy prognosis when given a diagno-
sis of a ‘non-specific IMD’ with little or no counseling about
the prognosis or inheritance of the disease. Consequently, most
cases are undiagnosed and result in either death or irreversible
psychomotor retardation.
In this backdrop, the Clinical Genetics Unit was established
by the Department of Paediatrics and Child Health, Aga Khan
University in October 2007. Housed with a trained staff geneti-
cist, it is the only nationwide institute providing comprehen-
sive and evidence based medical care to patients with IEMs.
The Aga Khan University Hospital (AKUH) is a
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Karachi, the hub of industry and business and thus populated
by diverse ethnicities from all over the country. Being the lar-
gest medical facility of Pakistan with many well-developed
sub-specialties it provides diagnostic and treatment facilities
to not only the population of Karachi but to referral cases
from across the country as well as from neighboring countries.
Thus the patient population coming to AKUH represents the
diversity of ethnicities in the country.Figure 1 Patient distribution according to age.
Table 1 Top ten reasons of referral to metabolic unit.
Clinical criteria Percentage of 426
patients referred
Psychomotor retardation 155 (36.4%)
Seizures 101 (23.7%)
Family history of sibling with
psychomotor retardation or death
95 (22.3%)
Coarse facies 61 (14.3%)
Hypotonia 57 (13.4%)
Failure to thrive 39 (9.2%)
Vomiting 31 (7.3%)
Microcephaly 26 (6.1%)
Neuroregression 26 (6.1%)
Dystonia 22 (5.2%)4. Subjects and methods
4.1. Study design
Retrospective notes review.
4.2. Study setting
The study was set in Department of Paediatrics, AKUH
Karachi in Pakistan. Pakistan is classified as a low-middle
income country in the World Bank List of economies (April
2012). During the 5 year period from January 2008 to
December 2012, no diagnostic tests for IMDs were undertaken
in Pakistan. All laboratory tests were sent to Malaysia and
analyzed at the Institute of Medical Research, Kuala Lumpur.
4.3. Study methods
This study is a chart review of patients who presented to the
Clinical Genetics Unit from January 2008 to December 2012
seeking diagnosis and treatment for their underlying IMD.
Information for the patients including age of presentation,
gender, consanguinity of parents, referring discipline, whether
patients were referred with a definite diagnosis or not and rea-
sons for referral was extracted from the charts and entered into
a structured questionnaire after approval from Institutional
Ethics Review Committee (Number 3177-PED-ERC-14). As
this is an exploratory study, only percentages and proportions
are reported.
5. Results
During the five year period, a total 1019 patients were seen in the
Clinical Genetics Unit of Department of Paediatrics, Aga Khan
University Hospital. This included 329 patients with genetic dis-
orders, 264 couples seeking antenatal or pre-marital genetic
counseling and 426 patients with IEMs. This paper is focused
on the cohort of IMD patients. The majority of patients seen
were born to consanguineous parents, 333 (78%) with a male
predominance of 255 (60%). Age was stratified into five groups
including neonates (<1 month), infants (1 month to less than
12 months), 1 year to less than 5 years, 5 years to less than
10 years and children greater than 10 years of age. The majority
of patients evaluated for IMDs were in the 1–5 years age group,
which was 151 (35%). The distribution of patients according to
age is shown in Fig. 1. The neurological symptoms including
developmental delay/psychomotor retardation, seizures, hypo-
tonia, microcephaly, neuroregression, dystonia, ataxia and
encephalopathy were the most frequent reasons for referral to
the Clinical Genetics Unit. The ten most frequent reasons forreferral observed in patients are listed in Table 1. Combination
of these symptoms and signs were seen in most patients. More
than one symptom and signwas often observed inmost patients.
A positive family history of a sib with psychomotor retardation
or death was the third most common reason to seek medical
help, which was observed in 95 (22%) of patients. The main
sources of referral were general pediatricians (33%); and neurol-
ogists (23.5%). Other referring disciplines were cardiology,
infectious diseases, dermatology and hematology departments.
Only 42 (10%) patients were referred with a pre-existing diagno-
sis. Of the 426 IMD patients seen during the study period, par-
ents of only 155 (36%) agreed for limitedmetabolic testing while
themajority 271 (64%) parents declined any testing. Among the
investigated group of patients, diagnoses were established for 85
(55%) patients equivalent to only 19.8% of the total. In 95% of
these 85 patients, a treatable disorder was identified with only
5% being found to be non-treatable. The non-treatable diseases
included lysosomal storage disorders (LSDs) with 2 patients
each with GM1 gangliosidosis and Farber disease. Other than
these 4 non-treatable LSD patients, 17 treatable LSDwere diag-
nosed. However, due to the high cost of enzyme replacement
therapy for these treatable LSDs, these patients could not afford
treatment. Thus for practical reasons, in this paper, the word
‘‘treatable” is limited to diseases like glycogen storage disorders
(GSDs), organic academia, urea cycle defects, vitamin respon-
sive disorders and fatty acid oxidation defects. In the ‘‘treatable
group” 60 patientswere included. The spectrumof diseases, with
the number of patients with each disease is summarized in
Table 2. The diagnoses were made on the basis of biochemical
Table 2 Spectrum of IMD in 85 diagnosed patients out of 426 patients who completed investigation.
Group IMD Number of patients
Carbohydrate metabolism Glycogen storage disorders
Type I (a) 2
Type III 2
Unspecified type 4
Fructose 1,6 bisphosphatase deficiency 4
Fanconi–Bickel syndrome 2
Lysosomal disorder Mucopolysaccharidosis
Type I 2
Type II 2
Type III 3
Unspecified type 6
Gauchers disease 4
Farber disease 2
GM1 gangliosidosis 2
Organic acidemia Methylmalonic acidemia 8
Propionic academia 4
Glutaric aciduria type I 3
Isovaleric acidemia 2
3-Hydroxy-isobutyric aciduria 1
Vitamin responsive disorder Intracellular Cb1C defect 4
Biotinidase deficiency 4
Holocarboxylase synthetase deficiency 1
Fatty acid oxidation and carnitine shuttle defects Medium chain acyl CoA dehydrogenase deficiency 3
Carnitine palmitoyl-transferase type 2 deficiency 2
Long chain acyl CoA dehydrogenase deficiency 1
Carnitine transporter defect 1
Aminoacidopathies and urea cycle defect Cystathionine beta synthetase deficiency 4
Urea cycle defects 3
Tyrosinemia-type I 2
Alkaptonuria 2
Ketogenesis and ketolytic defects Betaketothiolyase deficiency 3
3-Hydroxy-3-methylglutaryl CoA lyase deficiency 2
Total 85
262 B. Afroze et al.test and enzyme assays, but due to the limited availability and
cost of specialized laboratory tests, the specific type of GSDs
or mucopolysaccharidosis (MPS) was only discernable in about
half of these patients. Out of these 60 patients, 6 (10%) died
during the five year period. More than half; 34 (57%) did not
continue treatment and were lost to follow-up, whereas only
20 (33%) were treated and are under regular follow-up for five
years representing only 4.7% of the original total (Fig. 2).6. Discussion
This is the first study reporting systematic and organized data
of patients with IMDs over five years from the only Clinical
Genetics Unit in Pakistan. This study was conducted in the
period when there was no infrastructure available for diagnos-
tic tests locally and all tests were sent to overseas laboratories.
About two-thirds of the patients declined any kind of investi-
gations due to the high cost involved in testing and transporta-
tion of samples to overseas labs.
Of those with treatable IMDs, 57% were unable to con-
tinue treatment due to multiple reasons including localnon-availability of FSMP and medicines; parents inability to
import FSMP and medicines on a regular basis; expense of
both, high customs duty imposed by government on the
import of the FSMP and medicines, which they were supposed
to pay out-of-pocket till their children were able to support
their own treatment. Patients with IMDs often require fre-
quent hospitalizations, adding an extra financial challenge to
families in the current health care system in Pakistan. IMD
requiring FSMP is a life-long necessity for a patient, which
becomes enormous. This coerces parents to not only withdraw
treatment but also demand antenatal testing for genetic disor-
ders including IMD.
It is a general perception that antenatal testing followed by
selective termination of pregnancy (TOP) will be unacceptable
in a Muslim country like Pakistan. According to Islamic teach-
ings, human life begins with the inspiration of the soul, which
according to the Holy Qur’an and Prophet Mohammad teach-
ing is stated to be at the 120th day from the moment of concep-
tion. Prenatal diagnosis and TOP is allowed before 120 days of
gestation if the fetus has a fatal condition such that its life
would be a calamity for both the family and itself [14]. The
colonial-era Penal Code of 1860 with respect to abortion was
Figure 2 Flow chart showing patients seen, diagnosed and followed in five year period at the Clinical Genetics Unit, Aga Khan
University Hospital.
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in section 338 of the Pakistan Penal code, the conditions for
legal abortion depend on the developmental stage of the fetus;
whether the fetus’s organs are formed or not. Islamic scholars
have usually considered the fetus’s organs to be formed by
120 days of gestation. Before 120 days of gestation, abortions
are permitted to save the woman’s life or in order to provide
‘‘necessary treatment.” However, the term ‘‘necessary treat-
ment” is not clearly defined in law and is open for interpreta-
tion [15]. In our setting, parent’s complex attitude and
practices are observed with reference to TOP. The correspond-
ing author has reported 22% voluntary TOP without antenatal
testing for a possible underlying genetic disorder [16]. These
TOPs were opted by parents because of their anxiety and fear
of having another child with a genetic disorder. They had expe-
rienced the misery of their previous child, financial challengesto coupe the needs of a special child and poor availability of
multi-disciplinary support system needed for such disorders.
This experience exhibits 7.5 times higher TOP rates secondary
to possible genetic disorders than the overall TOP rates
reported in Pakistan, which is 29 per 1000 women of reproduc-
tive age [17].
The tradition of consanguineous marriages in Pakistan is
unlikely to change, thus requiring management of these disor-
ders at considerable financial cost. At present a heavy tax is
imposed on the FSMP purposed by the government, thus the
current estimated annual treatment cost is about USD
15,000 for most organic acidemias and amino acidopathies.
This huge cost in comparison to the estimated cost of antenatal
genetic testing (about USD 2500–3000) is more non-
affordable, making antenatal genetic testing as a much accept-
able option to parents. Cost effective preventive programs;
264 B. Afroze et al.including antenatal genetic testing and ‘‘cascade screening”;
premarital carrier testing for the siblings of the progeny and
parent’s siblings for IMDs is the need in Pakistan. In commu-
nities with high consanguinity and large family size, cascade
screening services are an effective alternative to population
screening for carrier detection. Family members have a better
sense and personal experience of the genetic disease in question
in their family. This allows more effective genetic counseling to
the couples at risk of having a child with a genetic disorder
about their reproductive options. Family members at risk of
being carrier for a genetic disorder can also be offered genetic
counseling, based on which they choose their partners to avoid
having children with genetic disorders. This approach has been
applied in Pakistan for the prevention of beta-thalassemia [18].
While proposing strategies to prevent more children being
born with IMD, we also acknowledge the need to address
the taxes imposed on the FSMP by the Pakistan government.
Pakistan is a country, where institutes like Sindh Institute of
Urology and Transplant in Karachi and Shaukat Khanum
Cancer Hospital in Lahore are providing free state of art med-
ical services to patients completely supported by philanthropy.
Awareness needs to be created for the IMDs among public and
government to support patients and families with IMDs.
7. Conclusion
This five year report of the first Clinical Genetics Unit in
Pakistan highlights the challenges in diagnosing and treating
patients with IMDs in a developing country with very limited
resources. Intervention strategies including tax reduction by
government on FSMP and philanthropy support for the treat-
ment of IMD patients is likely to result in better rates of con-
tinued treatment thus preventing the neurological damage
sustained by these patients in the absence of treatment.
Preventive strategies including prenatal genetic testing and cas-
cade screening for at risk individuals can help in reducing the
financial burden on the already stretched health care system of
Pakistan.
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